Suchergebnisse - "Willenbacher, Wolfgang"

PubPharm (9)

1

Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population

enthalten in: Leukemia & lymphoma | 2020

von Ludwig, H. | Pönisch, W. | Knop, S. | +20

2

Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

enthalten in: British journal of cancer | 2019

von Ludwig, H. | Poenisch, W. | Knop, S. | +14

3

Pomalidomide in primary intraocular lymphoma

enthalten in: Leukemia & lymphoma | 2019

von Bohn, J. | Willenbacher, W. | Haas, G. | +3

4

Second-generation immunomodulatory drugs in leptomeningeal myeloma

enthalten in: Leukemia & lymphoma | 2019

von Bohn, J. | Willenbacher, W. | Peschel, I. | +2

5

Multiple Myeloma Treatment in Real-world Clinical Practice : Results of a Prospective, Multinational, Noninterventional Study

enthalten in: Clinical lymphoma, myeloma & leukemia | 2018

von Mohty, M. | Terpos, E. | Mateos, M. | +130

6

A phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma

enthalten in: Blood | 2017

von Kiesewetter, B. | Willenbacher, E. | Willenbacher, W. | +9

7

Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma : Is It a Valid Treatment Option?

enthalten in: The oncologist | 2016

von Mondello, P. | Steiner, N. | Willenbacher, W. | +6

8

Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria : An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics

enthalten in: PloS one | 2016

von Willenbacher, E. | Weger, R. | Rochau, U. | +3

9

Long-term control in a patient with refractory multiple myeloma by oral cyclophosphamide and dexamethasone

enthalten in: Anticancer research | 2015

von Steiner, N. | Nachbaur, D. | König, P. | +2

1
[1]